Pacira Strengthens Market Position Amid Proxy Contest

H.C. Wainwright says the real-world data on Exparel indicate it can lead to lower or comparable total healthcare costs and reduced opioid usage. Pacira presented real-world data supporting the payer value proposition of liposomal bupivacaine, the analyst tells investors in a research note. The firm believes the strength of the evidence appears to depend on the specific procedure, with a more compelling economic signal observed in total hip arthroplasty compared to total knee arthroplasty. While the data in total hip arthroplasty pointed to meaningful cost savings, the total knee arthroplasty data points to cost parity, though that doesn't fully capture clinical benefits or patient satisfaction benefits that use of Exparel may provide, contends H.C. Wainwright. The firm believes the data highlights a reduction in opioid usage at six months post-surgery among patients with low back pain who underwent total hip arthroplasty. It keeps a Buy rating on Pacira with a $38 price target. The stock in midday trading is up 1% to $24.11.